{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:35:44Z","timestamp":1792290944727,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,10,26]],"date-time":"2011-10-26T00:00:00Z","timestamp":1319587200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s11060-011-0725-z","type":"journal-article","created":{"date-parts":[[2011,10,25]],"date-time":"2011-10-25T08:55:01Z","timestamp":1319532901000},"page":"61-67","source":"Crossref","is-referenced-by-count":87,"title":["Valproic acid sensitizes human glioma cells for temozolomide and \u03b3-radiation"],"prefix":"10.1007","volume":"107","author":[{"given":"Krista A.","family":"Van Nifterik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben J.","family":"Slotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Vincent M.","family":"Lafleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sminia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas J. A.","family":"Stalpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,26]]},"reference":[{"key":"725_CR1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"725_CR2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP et al (2009) European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459\u2013466","journal-title":"Lancet Oncol"},{"key":"725_CR3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0027-5107(97)00187-5","volume":"381","author":"B Kaina","year":"1997","unstructured":"Kaina B, Ziouta A, Ochs K et al (1997) Chromosomal instability, reproductive cell death and apoptosis induced by O6-methylguanine in Mex-, Mex\u00a0+\u00a0and methylation-tolerant mismatch repair compromised cells: facts and models. Mutat Res 381:227\u2013241","journal-title":"Mutat Res"},{"key":"725_CR4","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/mol.54.2.334","volume":"54","author":"S D\u2019Atri","year":"1998","unstructured":"D\u2019Atri S, Tentori L, Lacal PM et al (1998) Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54:334\u2013341","journal-title":"Mol Pharmacol"},{"key":"725_CR5","doi-asserted-by":"crossref","first-page":"8306","DOI":"10.1128\/MCB.23.22.8306-8315.2003","volume":"23","author":"Y Hirose","year":"2003","unstructured":"Hirose Y, Katayama M, Stokoe D et al (2003) The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol 23:8306\u20138315","journal-title":"Mol Cell Biol"},{"key":"725_CR6","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1073\/pnas.83.17.6292","volume":"83","author":"J Brennand","year":"1986","unstructured":"Brennand J, Margison GP (1986) Reduction of the toxicity and mutagenicity of alkylating agents in mammalian cells harboring the Escherichia coli alkyltransferase gene. Proc Natl Acad Sci USA 83:6292\u20136296","journal-title":"Proc Natl Acad Sci USA"},{"key":"725_CR7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrc1319","volume":"4","author":"SL Gerson","year":"2004","unstructured":"Gerson SL (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296\u2013307","journal-title":"Nat Rev Cancer"},{"key":"725_CR8","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1158\/1078-0432.CCR-03-0384","volume":"10","author":"ME Hegi","year":"2004","unstructured":"Hegi ME, Diserens AC, Godard S et al (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871\u20131874","journal-title":"Clin Cancer Res"},{"key":"725_CR9","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997\u20131003","journal-title":"N Engl J Med"},{"key":"725_CR10","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0360-3016(99)00539-8","volume":"47","author":"J Rijn Van","year":"2000","unstructured":"Van Rijn J, Heimans JJ, van den Berg J et al (2000) Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 47:779\u2013784","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"725_CR11","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1158\/1078-0432.CCR-06-0596","volume":"12","author":"A Chakravarti","year":"2006","unstructured":"Chakravarti A, Erkkinen MG, Nestler U et al (2006) Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 12:4738\u20134746","journal-title":"Clin Cancer Res"},{"key":"725_CR12","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ijrobp.2007.07.2366","volume":"69","author":"KA Nifterik Van","year":"2007","unstructured":"Van Nifterik KA, van den Berg J, Stalpers LJ et al (2007) Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys 69:1246\u20131253","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"725_CR13","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1158\/1078-0432.CCR-07-1856","volume":"14","author":"WJ Kil","year":"2008","unstructured":"Kil WJ, Cerna D, Burgan WE et al (2008) In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 14:931\u2013938","journal-title":"Clin Cancer Res"},{"key":"725_CR14","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M G\u00f6ttlicher","year":"2001","unstructured":"G\u00f6ttlicher M, Minucci S, Zhu P et al (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969\u20136978","journal-title":"EMBO J"},{"key":"725_CR15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.14712\/fb2007053020037","volume":"53","author":"M Kostrouchov\u00e1","year":"2007","unstructured":"Kostrouchov\u00e1 M, Kostrouch Z, Kostrouchov\u00e1 M (2007) Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol (Praha) 53:37\u201349","journal-title":"Folia Biol (Praha)"},{"key":"725_CR16","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","volume":"276","author":"CJ Phiel","year":"2001","unstructured":"Phiel CJ, Zhang F, Huang EY et al (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734\u201336741","journal-title":"J Biol Chem"},{"key":"725_CR17","doi-asserted-by":"crossref","first-page":"6066","DOI":"10.1158\/1078-0432.CCR-04-0537","volume":"10","author":"K Camphausen","year":"2004","unstructured":"Camphausen K, Scott T, Sproull M et al (2004) Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res 10:6066\u20136071","journal-title":"Clin Cancer Res"},{"key":"725_CR18","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.ijrobp.2004.03.001","volume":"59","author":"JH Kim","year":"2004","unstructured":"Kim JH, Shin JH, Kim IH (2004) Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys 59:1174\u20131180","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"725_CR19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2004.12.088","volume":"62","author":"P Chinnaiyan","year":"2005","unstructured":"Chinnaiyan P, Vallabhaneni G, Armstrong E et al (2005) Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62:223\u2013229","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"725_CR20","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1158\/1535-7163.MCT-05-0087","volume":"4","author":"M Entin-Meer","year":"2005","unstructured":"Entin-Meer M, Rephaeli A, Yang X et al (2005) Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Mol Cancer Ther 4:1952\u20131961","journal-title":"Mol Cancer Ther"},{"key":"725_CR21","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4161\/cbt.4.7.1922","volume":"4","author":"TC Karagiannis","year":"2005","unstructured":"Karagiannis TC, Harikrishnan KN, El-Osta A (2005) The histone deacetylase inhibitor, Trichostatin A, enhances radiation sensitivity and accumulation of gammaH2A. X. Cancer Biol Ther 4:787\u2013793","journal-title":"Cancer Biol Ther"},{"key":"725_CR22","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1158\/1078-0432.CCR-05-1230","volume":"12","author":"IA Kim","year":"2006","unstructured":"Kim IA, Shin JH, Kim IH et al (2006) Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53. Clin Cancer Res 12:940\u2013949","journal-title":"Clin Cancer Res"},{"key":"725_CR23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1215\/15228517-2006-032","volume":"9","author":"M Entin-Meer","year":"2007","unstructured":"Entin-Meer M, Yang X, VandenBerg SR et al (2007) In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro Oncol 9:82\u201388","journal-title":"Neuro Oncol"},{"key":"725_CR24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4161\/epi.1.3.2896","volume":"1","author":"TC Karagiannis","year":"2006","unstructured":"Karagiannis TC, Kn H, El-Osta A (2006) The epigenetic modifier, valproic acid, enhances radiation sensitivity. Epigenetics 1:131\u2013137","journal-title":"Epigenetics"},{"key":"725_CR25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1089\/cbr.2009.0629","volume":"24","author":"X Chen","year":"2009","unstructured":"Chen X, Wong P, Radany E, Wong JY (2009) HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm 24:689\u2013699","journal-title":"Cancer Biother Radiopharm"},{"key":"725_CR26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijrobp.2010.03.010","volume":"78","author":"C Blattmann","year":"2010","unstructured":"Blattmann C, Oertel S, Ehemann V et al (2010) Enhancement of radiation response in osteosarcoma and rhabomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 78:237\u2013245","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"725_CR27","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ijrobp.2009.09.052","volume":"76","author":"BG Debeb","year":"2010","unstructured":"Debeb BG, Xu W, Mok H et al (2010) Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. Int J Radiat Oncol Biol Phys 76:889\u2013895","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"725_CR28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ijc.20774","volume":"114","author":"K Camphausen","year":"2005","unstructured":"Camphausen K, Cerna D, Scott T et al (2005) Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 114:380\u2013386","journal-title":"Int J Cancer"},{"key":"725_CR29","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1158\/1078-0432.CCR-08-0643","volume":"14","author":"P Chinnaiyan","year":"2008","unstructured":"Chinnaiyan P, Cerna D, Burgan WE et al (2008) Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 14:5410\u20135415","journal-title":"Clin Cancer Res"},{"key":"725_CR30","doi-asserted-by":"crossref","first-page":"27586","DOI":"10.1074\/jbc.M303740200","volume":"278","author":"N Detich","year":"2003","unstructured":"Detich N, Bovenzi V, Szyf M (2003) Valproate induces replication-independent active DNA demethylation. J Biol Chem 278:27586\u201327592","journal-title":"J Biol Chem"},{"key":"725_CR31","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1471-4159.1986.tb00670.x","volume":"47","author":"AJ Balmforth","year":"1986","unstructured":"Balmforth AJ, Ball SG, Freshney RI et al (1986) D-1 dopaminergic and beta-adrenergic stimulation of adenylate cyclase in a clone derived from the human astrocytoma cell line G-CCM. J Neurochem 47:715\u2013719","journal-title":"J Neurochem"},{"key":"725_CR32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bjc.6605712","volume":"103","author":"KA Nifterik Van","year":"2010","unstructured":"Van Nifterik KA, van den Berg J, van der Meide WF et al (2010) Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. Br J Cancer 103:29\u201335","journal-title":"Br J Cancer"},{"key":"725_CR33","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","volume":"1","author":"NA Franken","year":"2006","unstructured":"Franken NA, Rodermond HM, Stap J et al (2006) Clonogenic assay of cells in vitro. Nat Protoc 1:2315\u20132319","journal-title":"Nat Protoc"},{"key":"725_CR34","first-page":"7291","volume":"63","author":"MS Kim","year":"2003","unstructured":"Kim MS, Blake M, Baek JH et al (2003) Inhibition of histonedeacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291\u20137300","journal-title":"Cancer Res"},{"key":"725_CR35","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3727\/096504007783338340","volume":"16","author":"E Ciusani","year":"2007","unstructured":"Ciusani E, Balzarotti M, Calatozzolo C et al (2007) Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines. Oncol Res 16:453\u2013463","journal-title":"Oncol Res"},{"key":"725_CR36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-007-9402-7","volume":"85","author":"CM Das","year":"2007","unstructured":"Das CM, Aguilera D, Vasquez H et al (2007) Valproic acid induces p21 and topoisomerase-II (alpha\/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 85:159\u2013170","journal-title":"J Neurooncol"},{"key":"725_CR37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1476-4598-6-36","volume":"6","author":"K Sasai","year":"2007","unstructured":"Sasai K, Akagi T, Aoyanagi E et al (2007) O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies. Mol Cancer 6:36","journal-title":"Mol Cancer"},{"key":"725_CR38","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/neuonc\/nop005","volume":"12","author":"J Fu","year":"2010","unstructured":"Fu J, Shao CJ, Chen FR et al (2010) Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro Oncol 12:328\u2013340","journal-title":"Neuro Oncol"},{"key":"725_CR39","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1023\/A:1005870122744","volume":"37","author":"M St\u00e4nder","year":"1998","unstructured":"St\u00e4nder M, Dichgans J, Weller M (1998) Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells. J Neurooncol 37:191\u2013198","journal-title":"J Neurooncol"},{"key":"725_CR40","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-004-2338-2","volume":"72","author":"S Oberndorfer","year":"2005","unstructured":"Oberndorfer S, Piribauer M, Marosi C et al (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 72:255\u2013260","journal-title":"J Neurooncol"},{"key":"725_CR41","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMc063696","volume":"356","author":"J Grewal","year":"2007","unstructured":"Grewal J, Dellinger CA, Yung WK (2007) Fatal reactivation of hepatitis B with temozolomide. N Engl J Med 356:1591\u20131592","journal-title":"N Engl J Med"},{"key":"725_CR42","first-page":"131","volume":"108","author":"B Neyns","year":"2008","unstructured":"Neyns B, Hoorens A, Stupp R (2008) Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. Acta Neurol Belg 108:131\u2013134","journal-title":"Acta Neurol Belg"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-011-0725-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-011-0725-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-011-0725-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T07:35:37Z","timestamp":1741851337000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-011-0725-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,26]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["725"],"URL":"https:\/\/doi.org\/10.1007\/s11060-011-0725-z","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,26]]}}}